nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—Orthostatic hypotension—Doxorubicin—testicular cancer	0.000779	0.000779	CcSEcCtD
Maraviroc—Abdominal pain upper—Doxorubicin—testicular cancer	0.000779	0.000779	CcSEcCtD
Maraviroc—Angina pectoris—Epirubicin—testicular cancer	0.000776	0.000776	CcSEcCtD
Maraviroc—Breast disorder—Doxorubicin—testicular cancer	0.000771	0.000771	CcSEcCtD
Maraviroc—Anorexia—Etoposide—testicular cancer	0.000771	0.000771	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000768	0.000768	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000768	0.000768	CcSEcCtD
Maraviroc—Decreased appetite—Cisplatin—testicular cancer	0.000767	0.000767	CcSEcCtD
Maraviroc—Bronchitis—Epirubicin—testicular cancer	0.000766	0.000766	CcSEcCtD
Maraviroc—Diarrhoea—Dactinomycin—testicular cancer	0.000764	0.000764	CcSEcCtD
Maraviroc—Pneumonia—Methotrexate—testicular cancer	0.000764	0.000764	CcSEcCtD
Maraviroc—Nasopharyngitis—Doxorubicin—testicular cancer	0.000763	0.000763	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000762	0.000762	CcSEcCtD
Maraviroc—Vomiting—Bleomycin—testicular cancer	0.000761	0.000761	CcSEcCtD
Maraviroc—Infestation NOS—Methotrexate—testicular cancer	0.000759	0.000759	CcSEcCtD
Maraviroc—Infestation—Methotrexate—testicular cancer	0.000759	0.000759	CcSEcCtD
Maraviroc—Depression—Methotrexate—testicular cancer	0.000757	0.000757	CcSEcCtD
Maraviroc—Pancytopenia—Epirubicin—testicular cancer	0.000757	0.000757	CcSEcCtD
Maraviroc—Rash—Bleomycin—testicular cancer	0.000755	0.000755	CcSEcCtD
Maraviroc—Pain—Cisplatin—testicular cancer	0.000755	0.000755	CcSEcCtD
Maraviroc—Dermatitis—Bleomycin—testicular cancer	0.000754	0.000754	CcSEcCtD
Maraviroc—Hypersensitivity—Ifosfamide—testicular cancer	0.000754	0.000754	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000753	0.000753	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000752	0.000752	CcSEcCtD
Maraviroc—Renal failure—Methotrexate—testicular cancer	0.000746	0.000746	CcSEcCtD
Maraviroc—Neutropenia—Epirubicin—testicular cancer	0.000745	0.000745	CcSEcCtD
Maraviroc—Abdominal distension—Doxorubicin—testicular cancer	0.000742	0.000742	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000741	0.000741	CcSEcCtD
Maraviroc—Stomatitis—Methotrexate—testicular cancer	0.00074	0.00074	CcSEcCtD
Maraviroc—Conjunctivitis—Methotrexate—testicular cancer	0.000738	0.000738	CcSEcCtD
Maraviroc—Influenza—Doxorubicin—testicular cancer	0.000737	0.000737	CcSEcCtD
Maraviroc—Asthenia—Ifosfamide—testicular cancer	0.000734	0.000734	CcSEcCtD
Maraviroc—Eosinophilia—Doxorubicin—testicular cancer	0.00073	0.00073	CcSEcCtD
Maraviroc—Paraesthesia—Etoposide—testicular cancer	0.000726	0.000726	CcSEcCtD
Maraviroc—Pruritus—Ifosfamide—testicular cancer	0.000724	0.000724	CcSEcCtD
Maraviroc—Pancreatitis—Doxorubicin—testicular cancer	0.000723	0.000723	CcSEcCtD
Maraviroc—Angina pectoris—Doxorubicin—testicular cancer	0.000718	0.000718	CcSEcCtD
Maraviroc—Hepatobiliary disease—Methotrexate—testicular cancer	0.000718	0.000718	CcSEcCtD
Maraviroc—Pneumonia—Epirubicin—testicular cancer	0.000715	0.000715	CcSEcCtD
Maraviroc—Nausea—Bleomycin—testicular cancer	0.000711	0.000711	CcSEcCtD
Maraviroc—Infestation NOS—Epirubicin—testicular cancer	0.00071	0.00071	CcSEcCtD
Maraviroc—Infestation—Epirubicin—testicular cancer	0.00071	0.00071	CcSEcCtD
Maraviroc—Vomiting—Dactinomycin—testicular cancer	0.00071	0.00071	CcSEcCtD
Maraviroc—Bronchitis—Doxorubicin—testicular cancer	0.000709	0.000709	CcSEcCtD
Maraviroc—Agranulocytosis—Methotrexate—testicular cancer	0.000708	0.000708	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000704	0.000704	CcSEcCtD
Maraviroc—Rash—Dactinomycin—testicular cancer	0.000704	0.000704	CcSEcCtD
Maraviroc—Decreased appetite—Etoposide—testicular cancer	0.000703	0.000703	CcSEcCtD
Maraviroc—Diarrhoea—Ifosfamide—testicular cancer	0.0007	0.0007	CcSEcCtD
Maraviroc—Pancytopenia—Doxorubicin—testicular cancer	0.0007	0.0007	CcSEcCtD
Maraviroc—Renal failure—Epirubicin—testicular cancer	0.000698	0.000698	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Etoposide—testicular cancer	0.000698	0.000698	CcSEcCtD
Maraviroc—Body temperature increased—Cisplatin—testicular cancer	0.000698	0.000698	CcSEcCtD
Maraviroc—Fatigue—Etoposide—testicular cancer	0.000697	0.000697	CcSEcCtD
Maraviroc—Neuropathy peripheral—Epirubicin—testicular cancer	0.000696	0.000696	CcSEcCtD
Maraviroc—Stomatitis—Epirubicin—testicular cancer	0.000693	0.000693	CcSEcCtD
Maraviroc—Jaundice—Epirubicin—testicular cancer	0.000693	0.000693	CcSEcCtD
Maraviroc—Pain—Etoposide—testicular cancer	0.000691	0.000691	CcSEcCtD
Maraviroc—Constipation—Etoposide—testicular cancer	0.000691	0.000691	CcSEcCtD
Maraviroc—Conjunctivitis—Epirubicin—testicular cancer	0.000691	0.000691	CcSEcCtD
Maraviroc—Neutropenia—Doxorubicin—testicular cancer	0.000689	0.000689	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000685	0.000685	CcSEcCtD
Maraviroc—Dizziness—Ifosfamide—testicular cancer	0.000677	0.000677	CcSEcCtD
Maraviroc—Pharyngitis—Methotrexate—testicular cancer	0.000676	0.000676	CcSEcCtD
Maraviroc—Urinary tract disorder—Methotrexate—testicular cancer	0.000673	0.000673	CcSEcCtD
Maraviroc—Hepatobiliary disease—Epirubicin—testicular cancer	0.000672	0.000672	CcSEcCtD
Maraviroc—Urethral disorder—Methotrexate—testicular cancer	0.000668	0.000668	CcSEcCtD
Maraviroc—Sinusitis—Epirubicin—testicular cancer	0.000667	0.000667	CcSEcCtD
Maraviroc—Nausea—Dactinomycin—testicular cancer	0.000663	0.000663	CcSEcCtD
Maraviroc—Agranulocytosis—Epirubicin—testicular cancer	0.000663	0.000663	CcSEcCtD
Maraviroc—Pneumonia—Doxorubicin—testicular cancer	0.000661	0.000661	CcSEcCtD
Maraviroc—Gastrointestinal pain—Etoposide—testicular cancer	0.000661	0.000661	CcSEcCtD
Maraviroc—Infestation NOS—Doxorubicin—testicular cancer	0.000657	0.000657	CcSEcCtD
Maraviroc—Infestation—Doxorubicin—testicular cancer	0.000657	0.000657	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000652	0.000652	CcSEcCtD
Maraviroc—Vomiting—Ifosfamide—testicular cancer	0.000651	0.000651	CcSEcCtD
Maraviroc—Hypersensitivity—Cisplatin—testicular cancer	0.00065	0.00065	CcSEcCtD
Maraviroc—Renal failure—Doxorubicin—testicular cancer	0.000646	0.000646	CcSEcCtD
Maraviroc—Rash—Ifosfamide—testicular cancer	0.000645	0.000645	CcSEcCtD
Maraviroc—Dermatitis—Ifosfamide—testicular cancer	0.000645	0.000645	CcSEcCtD
Maraviroc—Erythema multiforme—Methotrexate—testicular cancer	0.000644	0.000644	CcSEcCtD
Maraviroc—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000644	0.000644	CcSEcCtD
Maraviroc—Jaundice—Doxorubicin—testicular cancer	0.000641	0.000641	CcSEcCtD
Maraviroc—Stomatitis—Doxorubicin—testicular cancer	0.000641	0.000641	CcSEcCtD
Maraviroc—Rhinitis—Epirubicin—testicular cancer	0.000639	0.000639	CcSEcCtD
Maraviroc—Abdominal pain—Etoposide—testicular cancer	0.000639	0.000639	CcSEcCtD
Maraviroc—Body temperature increased—Etoposide—testicular cancer	0.000639	0.000639	CcSEcCtD
Maraviroc—Conjunctivitis—Doxorubicin—testicular cancer	0.000639	0.000639	CcSEcCtD
Maraviroc—Eye disorder—Methotrexate—testicular cancer	0.000637	0.000637	CcSEcCtD
Maraviroc—Asthenia—Cisplatin—testicular cancer	0.000633	0.000633	CcSEcCtD
Maraviroc—Pharyngitis—Epirubicin—testicular cancer	0.000633	0.000633	CcSEcCtD
Maraviroc—Cardiac disorder—Methotrexate—testicular cancer	0.000633	0.000633	CcSEcCtD
Maraviroc—Urinary tract disorder—Epirubicin—testicular cancer	0.00063	0.00063	CcSEcCtD
Maraviroc—Connective tissue disorder—Epirubicin—testicular cancer	0.000627	0.000627	CcSEcCtD
Maraviroc—Urethral disorder—Epirubicin—testicular cancer	0.000625	0.000625	CcSEcCtD
Maraviroc—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000622	0.000622	CcSEcCtD
Maraviroc—Angiopathy—Methotrexate—testicular cancer	0.000618	0.000618	CcSEcCtD
Maraviroc—Sinusitis—Doxorubicin—testicular cancer	0.000617	0.000617	CcSEcCtD
Maraviroc—Mediastinal disorder—Methotrexate—testicular cancer	0.000614	0.000614	CcSEcCtD
Maraviroc—Agranulocytosis—Doxorubicin—testicular cancer	0.000613	0.000613	CcSEcCtD
Maraviroc—Nausea—Ifosfamide—testicular cancer	0.000608	0.000608	CcSEcCtD
Maraviroc—Diarrhoea—Cisplatin—testicular cancer	0.000604	0.000604	CcSEcCtD
Maraviroc—Erythema multiforme—Epirubicin—testicular cancer	0.000603	0.000603	CcSEcCtD
Maraviroc—Alopecia—Methotrexate—testicular cancer	0.000602	0.000602	CcSEcCtD
Maraviroc—Mental disorder—Methotrexate—testicular cancer	0.000597	0.000597	CcSEcCtD
Maraviroc—Eye disorder—Epirubicin—testicular cancer	0.000596	0.000596	CcSEcCtD
Maraviroc—Hypersensitivity—Etoposide—testicular cancer	0.000596	0.000596	CcSEcCtD
Maraviroc—Erythema—Methotrexate—testicular cancer	0.000593	0.000593	CcSEcCtD
Maraviroc—Malnutrition—Methotrexate—testicular cancer	0.000593	0.000593	CcSEcCtD
Maraviroc—Cardiac disorder—Epirubicin—testicular cancer	0.000592	0.000592	CcSEcCtD
Maraviroc—Rhinitis—Doxorubicin—testicular cancer	0.000592	0.000592	CcSEcCtD
Maraviroc—Pharyngitis—Doxorubicin—testicular cancer	0.000586	0.000586	CcSEcCtD
Maraviroc—Urinary tract disorder—Doxorubicin—testicular cancer	0.000583	0.000583	CcSEcCtD
Maraviroc—Asthenia—Etoposide—testicular cancer	0.00058	0.00058	CcSEcCtD
Maraviroc—Connective tissue disorder—Doxorubicin—testicular cancer	0.00058	0.00058	CcSEcCtD
Maraviroc—Angiopathy—Epirubicin—testicular cancer	0.000579	0.000579	CcSEcCtD
Maraviroc—Urethral disorder—Doxorubicin—testicular cancer	0.000578	0.000578	CcSEcCtD
Maraviroc—Mediastinal disorder—Epirubicin—testicular cancer	0.000575	0.000575	CcSEcCtD
Maraviroc—Pruritus—Etoposide—testicular cancer	0.000572	0.000572	CcSEcCtD
Maraviroc—Alopecia—Epirubicin—testicular cancer	0.000564	0.000564	CcSEcCtD
Maraviroc—Vomiting—Cisplatin—testicular cancer	0.000561	0.000561	CcSEcCtD
Maraviroc—Mental disorder—Epirubicin—testicular cancer	0.000559	0.000559	CcSEcCtD
Maraviroc—Erythema multiforme—Doxorubicin—testicular cancer	0.000558	0.000558	CcSEcCtD
Maraviroc—Rash—Cisplatin—testicular cancer	0.000556	0.000556	CcSEcCtD
Maraviroc—Dermatitis—Cisplatin—testicular cancer	0.000556	0.000556	CcSEcCtD
Maraviroc—Malnutrition—Epirubicin—testicular cancer	0.000555	0.000555	CcSEcCtD
Maraviroc—Erythema—Epirubicin—testicular cancer	0.000555	0.000555	CcSEcCtD
Maraviroc—Diarrhoea—Etoposide—testicular cancer	0.000553	0.000553	CcSEcCtD
Maraviroc—Eye disorder—Doxorubicin—testicular cancer	0.000552	0.000552	CcSEcCtD
Maraviroc—Anaemia—Methotrexate—testicular cancer	0.000548	0.000548	CcSEcCtD
Maraviroc—Cardiac disorder—Doxorubicin—testicular cancer	0.000548	0.000548	CcSEcCtD
Maraviroc—Flatulence—Epirubicin—testicular cancer	0.000547	0.000547	CcSEcCtD
Maraviroc—Angiopathy—Doxorubicin—testicular cancer	0.000535	0.000535	CcSEcCtD
Maraviroc—Dizziness—Etoposide—testicular cancer	0.000535	0.000535	CcSEcCtD
Maraviroc—Mediastinal disorder—Doxorubicin—testicular cancer	0.000532	0.000532	CcSEcCtD
Maraviroc—Leukopenia—Methotrexate—testicular cancer	0.000531	0.000531	CcSEcCtD
Maraviroc—Nausea—Cisplatin—testicular cancer	0.000524	0.000524	CcSEcCtD
Maraviroc—Alopecia—Doxorubicin—testicular cancer	0.000521	0.000521	CcSEcCtD
Maraviroc—Cough—Methotrexate—testicular cancer	0.000518	0.000518	CcSEcCtD
Maraviroc—Mental disorder—Doxorubicin—testicular cancer	0.000517	0.000517	CcSEcCtD
Maraviroc—Convulsion—Methotrexate—testicular cancer	0.000514	0.000514	CcSEcCtD
Maraviroc—Vomiting—Etoposide—testicular cancer	0.000514	0.000514	CcSEcCtD
Maraviroc—Malnutrition—Doxorubicin—testicular cancer	0.000514	0.000514	CcSEcCtD
Maraviroc—Erythema—Doxorubicin—testicular cancer	0.000514	0.000514	CcSEcCtD
Maraviroc—Anaemia—Epirubicin—testicular cancer	0.000513	0.000513	CcSEcCtD
Maraviroc—Rash—Etoposide—testicular cancer	0.00051	0.00051	CcSEcCtD
Maraviroc—Dermatitis—Etoposide—testicular cancer	0.000509	0.000509	CcSEcCtD
Maraviroc—Headache—Etoposide—testicular cancer	0.000506	0.000506	CcSEcCtD
Maraviroc—Flatulence—Doxorubicin—testicular cancer	0.000506	0.000506	CcSEcCtD
Maraviroc—Myalgia—Methotrexate—testicular cancer	0.000505	0.000505	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000502	0.000502	CcSEcCtD
Maraviroc—Discomfort—Methotrexate—testicular cancer	0.000499	0.000499	CcSEcCtD
Maraviroc—Syncope—Epirubicin—testicular cancer	0.000498	0.000498	CcSEcCtD
Maraviroc—Leukopenia—Epirubicin—testicular cancer	0.000497	0.000497	CcSEcCtD
Maraviroc—Loss of consciousness—Epirubicin—testicular cancer	0.000488	0.000488	CcSEcCtD
Maraviroc—Cough—Epirubicin—testicular cancer	0.000484	0.000484	CcSEcCtD
Maraviroc—Convulsion—Epirubicin—testicular cancer	0.000481	0.000481	CcSEcCtD
Maraviroc—Infection—Methotrexate—testicular cancer	0.000481	0.000481	CcSEcCtD
Maraviroc—Nausea—Etoposide—testicular cancer	0.00048	0.00048	CcSEcCtD
Maraviroc—Nervous system disorder—Methotrexate—testicular cancer	0.000475	0.000475	CcSEcCtD
Maraviroc—Anaemia—Doxorubicin—testicular cancer	0.000475	0.000475	CcSEcCtD
Maraviroc—Myalgia—Epirubicin—testicular cancer	0.000473	0.000473	CcSEcCtD
Maraviroc—Anxiety—Epirubicin—testicular cancer	0.000471	0.000471	CcSEcCtD
Maraviroc—Skin disorder—Methotrexate—testicular cancer	0.00047	0.00047	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000469	0.000469	CcSEcCtD
Maraviroc—Discomfort—Epirubicin—testicular cancer	0.000467	0.000467	CcSEcCtD
Maraviroc—Anorexia—Methotrexate—testicular cancer	0.000462	0.000462	CcSEcCtD
Maraviroc—Syncope—Doxorubicin—testicular cancer	0.000461	0.000461	CcSEcCtD
Maraviroc—Leukopenia—Doxorubicin—testicular cancer	0.00046	0.00046	CcSEcCtD
Maraviroc—Oedema—Epirubicin—testicular cancer	0.000453	0.000453	CcSEcCtD
Maraviroc—Loss of consciousness—Doxorubicin—testicular cancer	0.000452	0.000452	CcSEcCtD
Maraviroc—Infection—Epirubicin—testicular cancer	0.00045	0.00045	CcSEcCtD
Maraviroc—Cough—Doxorubicin—testicular cancer	0.000448	0.000448	CcSEcCtD
Maraviroc—Shock—Epirubicin—testicular cancer	0.000446	0.000446	CcSEcCtD
Maraviroc—Convulsion—Doxorubicin—testicular cancer	0.000445	0.000445	CcSEcCtD
Maraviroc—Nervous system disorder—Epirubicin—testicular cancer	0.000444	0.000444	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000441	0.000441	CcSEcCtD
Maraviroc—Skin disorder—Epirubicin—testicular cancer	0.00044	0.00044	CcSEcCtD
Maraviroc—Insomnia—Methotrexate—testicular cancer	0.000438	0.000438	CcSEcCtD
Maraviroc—Myalgia—Doxorubicin—testicular cancer	0.000437	0.000437	CcSEcCtD
Maraviroc—Anxiety—Doxorubicin—testicular cancer	0.000436	0.000436	CcSEcCtD
Maraviroc—Paraesthesia—Methotrexate—testicular cancer	0.000435	0.000435	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000434	0.000434	CcSEcCtD
Maraviroc—Discomfort—Doxorubicin—testicular cancer	0.000432	0.000432	CcSEcCtD
Maraviroc—Anorexia—Epirubicin—testicular cancer	0.000432	0.000432	CcSEcCtD
Maraviroc—Decreased appetite—Methotrexate—testicular cancer	0.000421	0.000421	CcSEcCtD
Maraviroc—Oedema—Doxorubicin—testicular cancer	0.000419	0.000419	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000418	0.000418	CcSEcCtD
Maraviroc—Fatigue—Methotrexate—testicular cancer	0.000417	0.000417	CcSEcCtD
Maraviroc—Infection—Doxorubicin—testicular cancer	0.000417	0.000417	CcSEcCtD
Maraviroc—Pain—Methotrexate—testicular cancer	0.000414	0.000414	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000413	0.000413	CcSEcCtD
Maraviroc—Shock—Doxorubicin—testicular cancer	0.000412	0.000412	CcSEcCtD
Maraviroc—Nervous system disorder—Doxorubicin—testicular cancer	0.000411	0.000411	CcSEcCtD
Maraviroc—Insomnia—Epirubicin—testicular cancer	0.00041	0.00041	CcSEcCtD
Maraviroc—Skin disorder—Doxorubicin—testicular cancer	0.000407	0.000407	CcSEcCtD
Maraviroc—Paraesthesia—Epirubicin—testicular cancer	0.000407	0.000407	CcSEcCtD
Maraviroc—Anorexia—Doxorubicin—testicular cancer	0.0004	0.0004	CcSEcCtD
Maraviroc—Gastrointestinal pain—Methotrexate—testicular cancer	0.000396	0.000396	CcSEcCtD
Maraviroc—Decreased appetite—Epirubicin—testicular cancer	0.000394	0.000394	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000391	0.000391	CcSEcCtD
Maraviroc—Fatigue—Epirubicin—testicular cancer	0.000391	0.000391	CcSEcCtD
Maraviroc—Constipation—Epirubicin—testicular cancer	0.000387	0.000387	CcSEcCtD
Maraviroc—Pain—Epirubicin—testicular cancer	0.000387	0.000387	CcSEcCtD
Maraviroc—Abdominal pain—Methotrexate—testicular cancer	0.000383	0.000383	CcSEcCtD
Maraviroc—Body temperature increased—Methotrexate—testicular cancer	0.000383	0.000383	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000382	0.000382	CcSEcCtD
Maraviroc—Insomnia—Doxorubicin—testicular cancer	0.000379	0.000379	CcSEcCtD
Maraviroc—Paraesthesia—Doxorubicin—testicular cancer	0.000376	0.000376	CcSEcCtD
Maraviroc—Gastrointestinal pain—Epirubicin—testicular cancer	0.000371	0.000371	CcSEcCtD
Maraviroc—Decreased appetite—Doxorubicin—testicular cancer	0.000364	0.000364	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000362	0.000362	CcSEcCtD
Maraviroc—Fatigue—Doxorubicin—testicular cancer	0.000361	0.000361	CcSEcCtD
Maraviroc—Pain—Doxorubicin—testicular cancer	0.000359	0.000359	CcSEcCtD
Maraviroc—Constipation—Doxorubicin—testicular cancer	0.000359	0.000359	CcSEcCtD
Maraviroc—Body temperature increased—Epirubicin—testicular cancer	0.000358	0.000358	CcSEcCtD
Maraviroc—Abdominal pain—Epirubicin—testicular cancer	0.000358	0.000358	CcSEcCtD
Maraviroc—Hypersensitivity—Methotrexate—testicular cancer	0.000357	0.000357	CcSEcCtD
Maraviroc—Asthenia—Methotrexate—testicular cancer	0.000347	0.000347	CcSEcCtD
Maraviroc—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000343	0.000343	CcSEcCtD
Maraviroc—Pruritus—Methotrexate—testicular cancer	0.000343	0.000343	CcSEcCtD
Maraviroc—Hypersensitivity—Epirubicin—testicular cancer	0.000334	0.000334	CcSEcCtD
Maraviroc—Abdominal pain—Doxorubicin—testicular cancer	0.000331	0.000331	CcSEcCtD
Maraviroc—Body temperature increased—Doxorubicin—testicular cancer	0.000331	0.000331	CcSEcCtD
Maraviroc—Diarrhoea—Methotrexate—testicular cancer	0.000331	0.000331	CcSEcCtD
Maraviroc—Asthenia—Epirubicin—testicular cancer	0.000325	0.000325	CcSEcCtD
Maraviroc—Pruritus—Epirubicin—testicular cancer	0.000321	0.000321	CcSEcCtD
Maraviroc—Dizziness—Methotrexate—testicular cancer	0.00032	0.00032	CcSEcCtD
Maraviroc—Diarrhoea—Epirubicin—testicular cancer	0.00031	0.00031	CcSEcCtD
Maraviroc—Hypersensitivity—Doxorubicin—testicular cancer	0.000309	0.000309	CcSEcCtD
Maraviroc—Vomiting—Methotrexate—testicular cancer	0.000308	0.000308	CcSEcCtD
Maraviroc—Rash—Methotrexate—testicular cancer	0.000305	0.000305	CcSEcCtD
Maraviroc—Dermatitis—Methotrexate—testicular cancer	0.000305	0.000305	CcSEcCtD
Maraviroc—Headache—Methotrexate—testicular cancer	0.000303	0.000303	CcSEcCtD
Maraviroc—Asthenia—Doxorubicin—testicular cancer	0.000301	0.000301	CcSEcCtD
Maraviroc—Dizziness—Epirubicin—testicular cancer	0.0003	0.0003	CcSEcCtD
Maraviroc—Pruritus—Doxorubicin—testicular cancer	0.000297	0.000297	CcSEcCtD
Maraviroc—Vomiting—Epirubicin—testicular cancer	0.000288	0.000288	CcSEcCtD
Maraviroc—Nausea—Methotrexate—testicular cancer	0.000288	0.000288	CcSEcCtD
Maraviroc—Diarrhoea—Doxorubicin—testicular cancer	0.000287	0.000287	CcSEcCtD
Maraviroc—Rash—Epirubicin—testicular cancer	0.000286	0.000286	CcSEcCtD
Maraviroc—Dermatitis—Epirubicin—testicular cancer	0.000285	0.000285	CcSEcCtD
Maraviroc—Headache—Epirubicin—testicular cancer	0.000284	0.000284	CcSEcCtD
Maraviroc—Dizziness—Doxorubicin—testicular cancer	0.000277	0.000277	CcSEcCtD
Maraviroc—Nausea—Epirubicin—testicular cancer	0.000269	0.000269	CcSEcCtD
Maraviroc—Vomiting—Doxorubicin—testicular cancer	0.000267	0.000267	CcSEcCtD
Maraviroc—Rash—Doxorubicin—testicular cancer	0.000264	0.000264	CcSEcCtD
Maraviroc—Dermatitis—Doxorubicin—testicular cancer	0.000264	0.000264	CcSEcCtD
Maraviroc—Headache—Doxorubicin—testicular cancer	0.000263	0.000263	CcSEcCtD
Maraviroc—Nausea—Doxorubicin—testicular cancer	0.000249	0.000249	CcSEcCtD
